ADI is engaged in the research, development, manufacture and international sales of Onko-Sure(TM), an in vitro diagnostic (IVD) cancer test.
Under the terms of the agreement, Grifols USA will market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of colorectal cancer (CRC) to hospitals, clinical labs, clinics and other healthcare organizations throughout the US.
According to agreement, Grifols USA has the rights to market and distribute ADI's Onko-Sure cancer test specifically for the monitoring of colorectal cancer in the US.
Deal Type Partnership Sub-Category Marketing,Sales,Acquisition of Rights,Distribution Deal Status Announced: 2009-10-08
Deal Participants
Partner 1 (Company) Radient Pharmaceuticals Corporation (formerly AMDL, Inc.) Partner 2 (Company) AMDL Diagnostics, Inc. Partner 3 (Company) Grifols USA, LLC Partner 4 (Company) Grifols, S.A. (Formerly Probitas Pharma, S.A.)

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index